End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.38 USD | -9.38% |
|
-10.34% | -27.62% |
14/06 | Zura Bio Presents Data for the Tibulizumab (Zb-106) Program At Eular 2024 | CI |
06/06 | Zura Bio Limited Announces Formation of a Scientific Advisory Board | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.62% | 21Cr | |
+15.19% | 12TCr | |
+19.91% | 11TCr | |
+8.24% | 2.36TCr | |
-19.80% | 2.04TCr | |
-16.19% | 1.65TCr | |
-13.45% | 1.64TCr | |
-44.35% | 1.56TCr | |
+66.67% | 1.52TCr | |
+2.13% | 1.35TCr |
- Stock Market
- Equities
- ZURA Stock
- News Zura Bio Limited
- Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating